Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis

Company Overview

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Key Stats

• Today's Range: $1.01 to $1.12
• 50-Day Range: $1.01 to $12.00
• 52-Week Range: $0.98 to $392.00
• Volume: 524,307 shs
• Average Volume: 983,785 shs
• Market Capitalization: $3.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

CDT Stock Analysis - Frequently Asked Questions

How have CDT shares performed this year?

Conduit Pharmaceuticals' stock was trading at $6.86 at the beginning of the year. Since then, CDT stock has decreased by 84.1% and is now trading at $1.09.
View the best growth stocks for 2025 here.

When did Conduit Pharmaceuticals' stock split?

Shares of Conduit Pharmaceuticals reverse split before market open on Monday, January 27th 2025. The 1-100 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Conduit Pharmaceuticals' major shareholders?

Conduit Pharmaceuticals' top institutional shareholders include Rhumbline Advisers (1.00%), Barclays PLC (86.64%), Geode Capital Management LLC (56.79%) and Citadel Advisors LLC (51.09%). Insiders that own company stock include Ltd Nirland and Andrew Regan.
View institutional ownership trends.

How do I buy shares of Conduit Pharmaceuticals?

Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Conduit Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Conduit Pharmaceuticals investors own include BIOLASE (BIOL), Daré Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN).

Company Calendar

• Today: 3/14/2025
• Next Earnings (Estimated): 4/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDT
• Previous Symbol: NASDAQ:CDT
• CIK: 1896212
• Web: www.conduitpharma.com
• Phone: 760-471-8536
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -328.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.12
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.62) per share
• Price / Book: -1.75

Miscellaneous

• Outstanding Shares: 3,642,000
• Free Float: 710,000
• Market Cap: $3.95 million
• Optionable: Not Optionable
• Beta: 2.30